The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648.
 
Ian Chau
Honoraria - Eisai; Lilly; SERVIER
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; OncXerna Therapeutics; Pierre Fabre; Roche/Genentech; Sotio
Research Funding - Janssen-Cilag (Inst); Lilly (Inst)
 
Jaffer A. Ajani
Honoraria - Acrotech Biopharma; Aduro Biotech; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Pharmaceuticals; Fresenius Kabi; Gilead Sciences; GRAIL; Lilly; Merck; Novartis; oncotherics; SERVIER; zymeworks
Consulting or Advisory Role - American Cancer Society; BeiGene; Bristol-Myers Squibb; Insys Therapeutics; Merck; Vaccinogen
Research Funding - Amgen; Astellas Pharma (Inst); Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; Taiho Pharmaceutical; Takeda; Zymeworks
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly
 
Yuichiro Doki
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Jianming Xu
No Relationships to Disclose
 
Lucjan Wyrwicz
Consulting or Advisory Role - Amgen; SERVIER
Speakers' Bureau - Amgen; Roche; Sanofi; SERVIER
Patents, Royalties, Other Intellectual Property - National Cancer Research Institute (NCRI) (Inst)
 
Satoru Motoyama
Consulting or Advisory Role - Bristol-Myers Squibb; Chugai Pharma; MSD; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb; Kaken Pharmaceutical; Ono Pharmaceutical; Otsuka; Otsuka
Research Funding - BeiGene (Inst); Kaken Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Takashi Ogata
Other Relationship - Bristol-Myers Squibb; Ono Pharmaceutical
 
Hisato Kawakami
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo Co. Ltd.,; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst)
 
Chih-Hung Hsu
Honoraria - Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Ono Pharmaceutical; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; MSD; Ono Pharmaceutical; Roche/Genentech
Research Funding - AstraZeneca (Inst); BeiGene (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); MSD (Inst); Nucana (Inst); Ono Pharmaceutical (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst)
 
Antoine Adenis
Consulting or Advisory Role - Arcus Biosciences; Astellas Pharma; Bristol-Myers Squibb; Merck; Merck Serono
Speakers' Bureau - Bristol-Myers Squibb; MSD Oncology
Research Funding - Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; SERVIER
 
Farid El Hajbi
No Relationships to Disclose
 
Maria Di Bartolomeo
Honoraria - BMSi; Lilly; MSD Oncology; SERVIER
Consulting or Advisory Role - Lilly; MSD Oncology
Research Funding - Lilly
Travel, Accommodations, Expenses - Roche; Sanofi
 
Maria Ignez Freitas Melro Braghiroli
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; MSD; Roche; SERVIER
Consulting or Advisory Role - AstraZeneca Spain; Bayer; Bristol-Myers Squibb; Lilly; MSD; Roche; SERVIER
Research Funding - AstraZeneca Spain (Inst); Bristol-Myers Squibb (Inst); MSD (Inst)
Travel, Accommodations, Expenses - MSD
 
Eva Holtved
No Relationships to Disclose
 
Mariela A. Blum Murphy
Honoraria - Jounce Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
 
Sandzhar Abdullaev
Employment - Bristol Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb/Medarex
 
Samira Soleymani
Employment - Bristol-Myers Squibb
 
Ming Lei
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Yuko Kitagawa
Honoraria - Asahi Kasei; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Pharma; Ethicon; Kaken Pharmaceutical; MSD K.K.; Nippon Covidien; Olympus; Ono Pharmaceutical; Otsuka; Shionogi; Smith & Nephew; Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb K.K.; Ono Pharmaceutical
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); EA Pharma (Inst); Eisai (Inst); Kaken Pharmaceutical (Inst); Kyouwa Hakkou Kirin Co., Ltd. (Inst); Medicon (Inst); Nihon Pharma (Inst); Nippon Covidien (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); TSUMURA & CO. (Inst); Yakult Honsha (Inst)